Dr Sin Chi CHEW
Dr Yong Jae SHIN
Dr Lingyan WU
Ai Leng LIANG
Si Ying CHOO
Fiona Ni Ni MOE
Hepatocellular carcinoma (HCC) is a significant challenge in healthcare, with huge unmet clinical needs. HCC, also known as primary liver cancer, is the second-most important cause of cancer-related mortality worldwide, and 80% of HCC cases are found in the Asia-Pacific region. Only about 20% of HCC cases present with early-stage HCC potentially curable by surgery, transplantation and radiofrequency ablation. Even in these, cancer recurrence is a common phenomenon and overall survival for HCC remains poor. There is thus a compelling need for better therapies and a better understanding of the biology of HCC.
The Translational and Clinical Liver Research Programme at NCCS addresses these challenges through an integrated bench-to-bedside approach. Additionally, our programme is multi-institutional in nature and we work closely with leading research institutions (Translational Immunology Institute, Genome Institute of Singapore, Institute of Molecular and Cell Biology, Cancer Science Institute, Singapore, Singapore Phenome Center, Singapore General Hospital, National University Hospital). This multi-institutional collaboration has endowed us with the capability to conduct specialised and in-depth research into the multiple “- omics” of HCC and patient-derived models and apply them to precision medicine in HCC. It also houses the secretariat of the collaborative 21 year-old Asia-Pacific HCC Trials Group.
Over the past few years, our programme has received several notable grant awards,such as:
TUMOUR (TRANSVERSE); VENOUS PHASE 11-28
Subscribe to our mailing list to get the updates to your email inbox...
11 Hospital Drive, Singapore 169610 +65 6436 8000